Comparative Pharmacology
Head-to-head clinical analysis: PORTIA 21 versus TRI LO MILI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PORTIA 21 versus TRI LO MILI.
PORTIA-21 vs TRI-LO-MILI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Oral contraceptive: inhibition of ovulation by suppressing gonadotropin release; increases viscosity of cervical mucus, reducing sperm penetration; alters endometrial receptivity.
Combination oral contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on the hypothalamic-pituitary axis; norgestimate binds to progesterone receptors, inhibiting ovulation and altering cervical mucus and endometrial receptivity.
One tablet (norgestimate 0.180 mg/ethinyl estradiol 0.035 mg) orally once daily for 21 days, followed by 7 days of placebo.
One tablet orally once daily for 21 days, followed by 7 days of placebo.
None Documented
None Documented
Terminal elimination half-life: 24-30 hours; clinical context: steady-state reached after 5-7 days, allows once-daily dosing
Terminal elimination half-life: 20-24 hours; allows once-daily dosing for contraceptive efficacy.
Renal (50-60% unchanged), fecal (30-40% as metabolites), minor biliary
Renal: approximately 50% as metabolites; biliary/fecal: approximately 40% as metabolites; 10% unchanged in urine.
Category C
Category C
Oral Contraceptive
Oral Contraceptive